Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)

NCT04992182 is registered in ClinicalTrials.gov with Universidad del Desarrollo as lead sponsor.

NCT NCT04992182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)
Lead sponsor
Universidad del Desarrollo
Phase
Phase 2
Overall status
Unknown status
Start date
July 8, 2021
Completion date
June 30, 2022
Enrollment
534 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19